Intellia Therapeutics News - June 14, 2026

Intellia Reports 87% Drop in HAE Attacks, Meeting Phase 3 Endpoints

Intellia Therapeutics announced positive results from the global Phase 3 HAELO clinical trial of lonvo-z for hereditary angioedema (HAE). The European Academy...